Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $68.52M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 1.30M
Average 0.21M
ADAG Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Adagene Inc.NASDAQ: ADAG
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income declines year over year
Q4 FY2025 net income of $4.14M (cash outflow) fell 83.4% year over year, behind the -12.6% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -39.6% a year.
Context
- Net income amounted to 229.6% of revenue in FY2025, down 32156.9 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$21.98M (+24.8%) for the fiscal year ending Dec 2026, a step up from the -47.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$4.14M— QoQ
- Last fiscal yearDec 2025
- -$17.61M-47.3% YoY
- LTMJun 2024
- -$31.85M-12.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -83.4% | — | — |
| 1 year | -47.3% | +24.8% | +72.1 pp |
| 3-year CAGR | -39.6% | +11.0% | +50.6 pp |
| 5-year CAGR | +11.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (17.61M) USD
- Year-over-year change
- +47.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.61M) | +47.3% |
| FY2024 | 2024-12-31 | (33.42M) | -76.4% |
| FY2023 | 2023-12-31 | (18.95M) | +76.3% |
| FY2022 | 2022-12-31 | (79.97M) | -9.3% |
| FY2021 | 2021-12-31 | (73.18M) | — |
Net Income vs competitors
How ADAG compares with its peers on the latest reported figures
- ADAG's LTM Jun 2024 net income of $31.85M is the 6th largest of the 9 companies compared; the peer median is $32.35M.
- Net income amounts to 3904.3% of revenue for ADAG, versus a peer median of 759.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Apr 2026 | $8.08M | -19.0% | +22.4% | 448.4% | |
| Peer median (excluding ADAG) | $32.35M | +1.6% | +15.1% | 759.3% | |
Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.18M) | (79.97M) | (18.95M) | (33.42M) | (17.61M) |
| Depreciation & Amortization | 1.13M | 1.45M | 1.21M | 926.25K | 589.79K |
| Deferred Income Tax | 622.43K | (44.16K) | 0 | 0 | 0 |
| Stock-Based Compensation | 18.68M | 10.52M | 7.27M | 4.91M | 3.74M |
| Change in Working Capital | 9.35M | 21.94M | (16.55M) | (1.89M) | (775.3K) |
| Accounts Receivables | (3M) | 6.89M | 397.41K | 213.72K | (9.04K) |
| Inventory | 6.02M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.51M | 344.51K | (572.37K) | 1.15M | (1.36M) |
| Other Working Capital | 4.82M | 14.75M | (16.38M) | (3.25M) | 591.01K |
| Other Non-Cash Items | (9.95K) | (2.5M) | (1.44M) | (222.24K) | (1.6M) |
| Operating Cash Flow | (43.41M) | (48.61M) | (28.45M) | (29.7M) | (15.66M) |
| Capital Expenditures | (2.51M) | (690.94K) | (85.01K) | (33.58K) | (17.05K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (47M) | (128.5M) | (80M) |
| Sales of Investments | 0 | 0 | 47M | 129.64M | 80.49M |
| Other Investing Activities | 0 | 4.89K | 7.66K | 169 | 1.4K |
| Investing Cash Flow | (2.51M) | (686.05K) | (77.36K) | 1.11M | 476.8K |
| Debt Repayment | (702.86K) | 21.48M | (5.37M) | (3.42M) | (12.24M) |
| Common Stock Issued | 149.79M | 0 | 5.5K | 7.33M | 138.28K |
| Common Stock Repurchased | (2.36M) | (3.98M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.37M) | 323.21K | 5.5K | (137.3K) | 0 |
| Financing Cash Flow | 145.36M | 17.82M | (5.37M) | 3.77M | 4.45M |
| Effect of Forex Changes | (192.35K) | 842.2K | 74.72K | 81.88K | 64.55K |
| Net Change in Cash | 99.24M | (30.63M) | (33.82M) | (24.74M) | (10.67M) |
| Free Cash Flow | (45.92M) | (49.3M) | (28.54M) | (29.73M) | (15.67M) |
Adagene Inc.
NASDAQ:ADAG
Intrinsic Alpha fair value
Locked
Current Price
$1.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.